Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
An. bras. dermatol ; 91(5,supl.1): 42-44, Sept.-Oct. 2016. graf
Article in English | LILACS | ID: biblio-837922

ABSTRACT

Abstract We report a 33-year-old male patient diagnosed with erythroplasia of Queyrat. The patient had an erythematous and eroded lesion affecting more than 50% of the glans associated with bleeding and local pain. Despite previous indication of penectomy, he was successfully treated with topical 5-fluorouracil.


Subject(s)
Humans , Male , Adult , Penile Neoplasms/drug therapy , Carcinoma in Situ/drug therapy , Carcinoma, Squamous Cell/drug therapy , Erythroplasia/drug therapy , Fluorouracil/administration & dosage , Antimetabolites, Antineoplastic/administration & dosage , Penile Neoplasms/pathology , Penis/pathology , Time Factors , Biopsy , Carcinoma in Situ/pathology , Carcinoma, Squamous Cell/pathology , Administration, Topical , Treatment Outcome , Erythroplasia/pathology
2.
Rev. bras. oftalmol ; 75(5): 391-395, sept.-out. 2016. tab
Article in Portuguese | LILACS | ID: lil-798072

ABSTRACT

RESUMO Objetivo: Avaliar a segurança e eficácia de três técnicas distintas para o tratamento de neoplasia intraepitelial córneo-conjuntival. Métodos: Vinte e seis pacientes, 11 mulheres e 15 homens, com idade entre 32 e 88 anos (média 64,84 anos), atendidos entre 1999 e 2014, foram incluídos neste estudo. Todos os pacientes foram submetidos à exérese da lesão com margem de segurança de 4mm e crioterapia a 2mm do limbo. Conforme o tratamento complementar, os pacientes foram divididos em três grupos: Grupo 1 (8 olhos): recobrimento conjuntival e 2 ciclos de mitomicina C 0,02% (MMC) 4x/dia por 10 dias, com intervalo de 30 dias entre os ciclos. Grupo 2 (9 olhos): recobrimento com membrana amniótica e 3 ciclos de MMC 3x/dia por 10 dias, com intervalo de 10 dias entre o 1º e o 2º ciclo e 30 dias entre 2º e o 3º ciclo. Grupo 3 (9 olhos): recobrimento com membrana amniótica sem o uso de MMC. O acompanhamento dos pacientes variou de 3 meses a 14 anos (média: 4 anos). Resultados: Vinte e três pacientes apresentaram erradicação da lesão com um único tratamento. Três pacientes do Grupo 3 apresentaram recidiva da lesão após 3 meses, 6 meses e 1 ano do tratamento. Dois deles foram retratados pela técnica 1, sem nova recidiva após seguimento de 3 e 4 anos; o outro paciente foi submetido à enucleação. Não foram observados efeitos colaterais relacionados ao uso da mitomicina C durante o seguimento. Conclusão: Após exérese da lesão e crioterapia, os pacientes tratados com recobrimento conjuntival ou membrana amniótica associado à mitomicina C mostraram tendência a resultados mais eficazes.


ABSTRACT Purpose: To evaluate the safety and efficacy of three different techniques for the treatment of conjunctival-corneal intraepithelial neoplasia. Methods: Twenty-six eyes of 26 patients, 11 women and 15 men were included in a nonrandomized, retrospective, observational case series. Mean patient age was 64 years (range, 32-88 years).All patients were treated from 1999 to 2014. Mean postoperative follow-up was 4 years (range, 3 months to 14 years). All patients underwent excision of the lesion with a 4-mm safety margin and a 2-mm from the limbus cryotherapy. As further treatment the patients were divided into three groups: Group 1 (8 eyes): conjunctival autograft and 2 cycles of mitomycin C 0.02% (MMC) eye drops, four times daily for 10 days with an interval of 30 days between cycles. Group 2 (9 eyes): amniotic membrane (AM) graft and 3 cycles of MMC eye drops, three times daily for 10 days with an interval of 10 days between the 1st and 2nd cycle and 30 days between the 2nd and 3rd cycle. Group 3 (9 eyes): AM graft without MMC eye drops. Results: After a single treatment, the lesions were eradicated in twenty-three patients. Recurrence was noted in three patients from Group 3 at 3 months, 6 months and 1 year after treatment. Two of them were retreated by the technique used in Group 1 without further recurrence; the other patient underwent enucleation. No adverse effects related to the use of mitomycin C were observed during. There were no side effects related to the use of mitomycin C during follow-up. Conclusion: After surgical excision and cryotherapy, patients treated with conjunctival or amniotic membrane graft associated with mitomycin C, showed a tendency to more effective results.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Carcinoma in Situ/therapy , Mitomycin/therapeutic use , Cryotherapy , Conjunctival Neoplasms/therapy , Corneal Diseases/therapy , Amnion/transplantation , Ophthalmologic Surgical Procedures/methods , Carcinoma in Situ/surgery , Carcinoma in Situ/pathology , Carcinoma in Situ/drug therapy , Prospective Studies , Follow-Up Studies , Treatment Outcome , Limbus Corneae , Combined Modality Therapy , Conjunctival Neoplasms/surgery , Conjunctival Neoplasms/pathology , Conjunctival Neoplasms/drug therapy , Corneal Diseases/surgery , Corneal Diseases/pathology , Corneal Diseases/drug therapy , Neoplasm Recurrence, Local
3.
Article in English | IMSEAR | ID: sea-156255

ABSTRACT

Background. Neoadjuvant chemotherapy is now the standard approach for most large breast cancers including locally advanced cancers of the breast. The majority of patients respond satisfactorily to chemotherapy with effective downsizing of tumours to consider breast conservation surgery. Pathological complete response (pathCR) is known to be a strong predictor of good outcome; however, many factors are known to influence the extent of response to chemotherapy. It has been observed that smaller the tumour, better is the response achieved in contrast to larger and locally advanced tumours where only one-third may respond well enough to merit breast conservation. Various other clinical, biological and molecular factors are also being evaluated as effective predictors of chemosensitivity. Most of these are either not easily available for all patients in developing countries or are overtly expensive and not applicable for all patients. Methods. We evaluated the clinical and pathological predictors of response to chemotherapy in 1402 women with locally advanced breast cancer. Results. There was a higher rate of pathCR in smaller tumours, younger women and ER-negative as well as triple negative tumours. The presence of ductal carcinoma in situ (DCIS) and lymphatic and vascular invasion (LVI) were associated with lower pathCR. Conclusion. In the absence of ready availability of expensive molecular and genomic assays, clinical parameters and standard histopathological variables can also be useful indicators of response to neoadjuvant chemotherapy. Additionally, they can help identify those who could be eventually conserved or have a better outcome.


Subject(s)
Adult , Aged , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Carcinoma in Situ/drug therapy , Carcinoma in Situ/metabolism , Carcinoma in Situ/pathology , Carcinoma, Ductal/drug therapy , Carcinoma, Ductal/metabolism , Carcinoma, Ductal/pathology , Drug Resistance, Neoplasm , Female , Humans , Middle Aged , Predictive Value of Tests , Biomarkers, Tumor/metabolism
4.
Arq. bras. oftalmol ; 69(3): 407-411, maio-jun. 2006. ilus
Article in Portuguese | LILACS | ID: lil-433808

ABSTRACT

São relatados três casos de neoplasia intra-epitelial córneo-conjuntival nos quais a mitomicina C foi utilizada em abordagens distintas de acordo com a situação clínica encontrada. Os pacientes selecionados foram atendidos no Departamento de Oftalmologia da Casa de Saúde Santo Inácio, com diagnóstico clínico e/ou histopatológico de neoplasia intra-epitelial córneo-conjuntival. Com base na apresentação clínica das lesões, utilizou-se a mitomicina C a 0,04 por cento em três abordagens terapêuticas distintas: 1) quimioablação pós-operatória; 2) quimiorredução pré-operatória; e 3) quimioablação isolada. Obteve-se regressão da lesão tumoral nos três casos, sem recorrência em tempo de seguimento variando de 18-29 meses. Hiperemia conjuntival em um dos casos foi a única complicação observada. A mitomicina C mostrou-se eficaz e segura para tratamento de neoplasia intra-epitelial córneo-conjuntival, possibilitando várias abordagens terapêuticas de acordo com as características das lesões.


Subject(s)
Humans , Male , Female , Middle Aged , Aged, 80 and over , Antibiotics, Antineoplastic/administration & dosage , Carcinoma in Situ/drug therapy , Conjunctival Neoplasms/drug therapy , Corneal Diseases/drug therapy , Mitomycin/administration & dosage , Administration, Topical , Carcinoma in Situ/surgery , Conjunctival Neoplasms/surgery , Corneal Diseases/surgery , Eye Neoplasms/drug therapy , Eye Neoplasms/surgery , Follow-Up Studies , Treatment Outcome
5.
Int. braz. j. urol ; 30(5): 400-402, Sept.-Oct. 2004. ilus
Article in English | LILACS | ID: lil-388880

ABSTRACT

We report an 81-year-old male who developed severe interstitial pneumonitis on maintenance intravesical Bacillus Calmette-Guerin (BCG) for in-situ carcinoma of the bladder. The patient was treated with steroids and anti-tuberculin therapy with complete response. While there is no established standard of care for the treatment of interstitial pneumonitis, recent reports describe success with combination of corticosteroids and anti-tuberculin medications. We elected to follow this precedent and treated our patient with corticosteroids and anti-tuberculin therapy with good outcome.


Subject(s)
Aged , Aged, 80 and over , Humans , Male , Adjuvants, Immunologic/adverse effects , BCG Vaccine/adverse effects , Carcinoma in Situ/drug therapy , Lung Diseases, Interstitial/chemically induced , Urinary Bladder Neoplasms/drug therapy , Administration, Intravesical , Adjuvants, Immunologic/administration & dosage , BCG Vaccine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL